HK1037517A1 - Use of apomorphine in the treatment of premature ejaculation - Google Patents

Use of apomorphine in the treatment of premature ejaculation

Info

Publication number
HK1037517A1
HK1037517A1 HK01106459A HK01106459A HK1037517A1 HK 1037517 A1 HK1037517 A1 HK 1037517A1 HK 01106459 A HK01106459 A HK 01106459A HK 01106459 A HK01106459 A HK 01106459A HK 1037517 A1 HK1037517 A1 HK 1037517A1
Authority
HK
Hong Kong
Prior art keywords
apomorphine
treatment
premature ejaculation
ejaculation
premature
Prior art date
Application number
HK01106459A
Other languages
English (en)
Inventor
Jeremy P W Heaton
Michael A Adams
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of HK1037517A1 publication Critical patent/HK1037517A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01106459A 1998-05-29 2001-09-12 Use of apomorphine in the treatment of premature ejaculation HK1037517A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/086,630 US6403605B1 (en) 1998-05-29 1998-05-29 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
PCT/CA1999/000508 WO1999062502A2 (en) 1998-05-29 1999-05-28 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation

Publications (1)

Publication Number Publication Date
HK1037517A1 true HK1037517A1 (en) 2002-02-15

Family

ID=22199842

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106459A HK1037517A1 (en) 1998-05-29 2001-09-12 Use of apomorphine in the treatment of premature ejaculation

Country Status (11)

Country Link
US (3) US6403605B1 (de)
EP (2) EP1082118B1 (de)
AR (1) AR019579A1 (de)
AT (1) ATE326969T1 (de)
AU (1) AU764009B2 (de)
CA (1) CA2331387A1 (de)
DE (1) DE69931487T2 (de)
ES (1) ES2268869T3 (de)
HK (1) HK1037517A1 (de)
TW (1) TWI232748B (de)
WO (1) WO1999062502A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
WO2005107810A2 (en) 2004-05-11 2005-11-17 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
KR20150089085A (ko) * 2007-02-12 2015-08-04 브릭스 파마슈티컬스 인코퍼레이티드 조루 및 발기부전을 동시에 치료하는 방법
WO2008100933A2 (en) * 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Reducing side effects of tramadol
US20110150946A1 (en) * 2008-08-22 2011-06-23 Al-Ghananeem Abeer M Transdermal Delivery of Apomorphine Using Microneedles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
ATE241984T1 (de) 1993-03-26 2003-06-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin
ATE189121T1 (de) 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
IL123583A (en) 1995-10-13 2003-07-31 Neurosearch As 3-substituted -8-azabicyclo [3,2,1] oct-2-ene derivatives, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1999062502A3 (en) 2000-06-15
US20030092725A1 (en) 2003-05-15
ATE326969T1 (de) 2006-06-15
AU764009B2 (en) 2003-08-07
EP1082118A2 (de) 2001-03-14
ES2268869T3 (es) 2007-03-16
CA2331387A1 (en) 1999-12-09
AR019579A1 (es) 2002-02-27
TWI232748B (en) 2005-05-21
US6403605B1 (en) 2002-06-11
WO1999062502A2 (en) 1999-12-09
DE69931487T2 (de) 2007-05-03
EP1666040A1 (de) 2006-06-07
DE69931487D1 (de) 2006-06-29
EP1082118B1 (de) 2006-05-24
US20060281752A1 (en) 2006-12-14
AU4027299A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
GB0106183D0 (en) Improvements in or relating to the treatment of lesions
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
HUP0200549A3 (en) Apomorphine and sildenafil composition and their use
HUP0200442A3 (en) Azeotrope-like composition comprising 1,1,1,3,3-pentafluorobutane and its use
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
IL143410A0 (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
HK1037517A1 (en) Use of apomorphine in the treatment of premature ejaculation
IL127351A0 (en) Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV
HUP0203811A3 (en) Use of polymeric material in the treatment of hard surfaces
GB9912159D0 (en) Improvements in and relating to the treatment of water
GB9816234D0 (en) Compounds for use in the treatment of inflammation
EP1079764A4 (de) Behandlung sexueller störungen bei bestimmten patientengruppen
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
AP9901683A0 (en) Treatment of water
AU4676099A (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
IL143413A0 (en) Method for the activation of water and use thereof
EP1328264A4 (de) Verwendung von estramustin-phosphat in der behandlung von knochenmetastasen
EP1032266A4 (de) Verwendung von delta-5-androsten-3-beta-ol-7,17-dion in der behandlung der arthritis
AU3061199A (en) Skin treatment compositions and the use thereof
GB9904252D0 (en) Composition for the treatment of pain
HK1048767A1 (zh) 治療疼痛的方法和組合物
HK1055288A1 (en) Novel aqueous composition and use of the same
GB9805686D0 (en) Treatment of metals
SI1047428T1 (sl) Uporaba morfolinola za zdravljenje seksualne disfunkcije

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100528